Date
Our series of video interviews on Belgian Nuclear Medicine concludes with Precirix.
The full publication, featuring 9 success stories and 19 stakeholders, was recently published, consult the publication here.
Ruth Devenyns, former CEO of Precirix (now Tom Plitz), took us on a journey to learn about the Belgian biotech company, Precirix, which pioneers innovative cancer treatments by utilizing camel-derived antibodies to precisely target cancer cells: